Product Description
an investigational DNA vaccine being developed for the prevention of relapse of tuberculosis. (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT03159975)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yonsei University
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Tuberculosis, Pulmonary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03159975 |
NCT03159975 | P1 |
Withdrawn |
Tuberculosis, Pulmonary |
2018-08-01 |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|